Impact of Anti-nuclear Antibody Seropositivity on Clinicopathological Parameters, Treatment Response, and Survival in Lymphoma Patients.
Mahendra KumarGaurav PrakashAmanjit BalAnu KumariYashwant KumarRanjeet BhardwajPankaj MalhotraRanjana W MinzPublished in: Asian Pacific journal of cancer prevention : APJCP (2024)
ANA is more frequent in lymphoma and increases further after chemotherapy. Higher mean age, early stage, and infrequent B symptoms were found to be significantly more frequent in ANA-positive lymphoma patients; however, only limited evidence supports its role as a prognostic marker or response to therapy. A wider study with appropriate follow-up data and molecular assay could shed light on the immunobiology of ANA production and its more defined clinical utility in lymphoma.
Keyphrases
- end stage renal disease
- early stage
- diffuse large b cell lymphoma
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- patient reported outcomes
- machine learning
- physical activity
- locally advanced
- deep learning
- cell therapy
- single cell
- single molecule
- rectal cancer
- sleep quality